# Inge Marie Svane

Source: https://onco.cc/people/inge-marie-svane/  
OnCo record `inge-marie-svane` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the Dutch-Danish trial that proved TIL therapy beats ipilimumab in melanoma, the first randomised win for a cell therapy in a solid tumour.

## Summary

Inge Marie Svane (Herlev, Denmark) co-led with John Haanen the randomised phase 3 trial showing tumour-infiltrating lymphocyte therapy doubles progression-free survival compared with ipilimumab in advanced melanoma, the first randomised evidence for any cell therapy in a solid tumour. She built Denmark's academic TIL manufacturing programme and leads trials of TIL in other cancers and of peptide vaccines targeting IDO and PD-L1.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: cell-therapy; til; melanoma
- Role: Director, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital Herlev
- Specialisms: Tumour-infiltrating lymphocyte therapy; Melanoma immunotherapy; Cancer vaccines; Cell therapy manufacturing

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Svane%20IM%5BAuthor%5D%20tumor-infiltrating%20lymphocytes%20melanoma

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [TIL therapy](https://onco.cc/technologies/til-therapy/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Lifileucel](https://onco.cc/drugs/lifileucel/)
- institutions: [Herlev Hospital, Copenhagen University Hospital](https://onco.cc/institutions/herlev-hospital/)
- key papers: [Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma](https://onco.cc/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/)

---
JSON: https://onco.cc/api/v1/entities/inge-marie-svane.json